GIO World Health Ltd, a Leading Stem Cell Life Science Company, Announces Plans to Go Public

• GIO World Health Ltd (“GIO World Health”) has entered into a business combination agreement with Apeiron Capital Investment Corp (APNC).

• The post-closing combined public company, which will be named GIO World Health Holdings, Inc., values GIO World Health in the proposed transaction at a pre-money enterprise value of $250 million.

• Current GIO World Health shareholders will retain 100% of their equity in the post-closing combined public company and will continue to own approximately 80.83% of the post-closing combined public company on a pro forma basis, assuming no redemptions by Apeiron Capital’s public shareholders, and that all GIO World Health shareholders participate in the transaction.

GIO World Health, a recently formed company focused on stem cell research and development, and Apeiron Capital Investment Corp. (“Apeiron Capital”) (OTC: APNC), a publicly traded special purpose acquisition company, announced that they have entered into a definitive business combination agreement (the “BCA”) to bring GIO World Health public in order to bring its proprietary stem cell treatments to market, and other stem cell based products for global consumption.  The parties intend that at the closing of the proposed transaction (the “Closing”), Apeiron Capital common stock will be listed on either the New York Stock Exchange or NASDAQ, and Apeiron Capital will be renamed “GIO World Health Holdings, Inc.”.

AiThority Interview : AiThority Interview with Shaun McGirr, Field CDO at Dataiku

GIO World Health, was founded in 2021 by Dr. Anand Srivastava and Deven Patel, accomplished professionals who have operated in the stem cell research and development field for over two decades.  Beginning in the late 1990’s, Dr. Anand Srivastava has been pursuing pioneering stem cell research and potential applications at some of the leading academic universities around the world.  He has published extensively in top academic journals and has received numerous awards recognizing him for his contributions to the sciences.

Read More Interview: AiThority Interview with Mario Ciabarra, Founder and CEO of Quantum Metric

GIO World Health is a stem cell-based life science company with plans to distribute selective products and services globally, and may also pursue FDA approval for more advanced therapies.  GIO World Health is planning to mass produce the Red Blood Cells (RBCs) from stem cells in a bioreactor to solve the blood shortage problem.  Furthermore, they also plan to provide proprietary stem cell-based therapies through their Longevity (“Anti-Aging”) clinics, which are expected to commence in the second half of 2023 with continuing expansion efforts in subsequent years.  The clinics will focus initially on targeted non-U.S. locations and utilize the role of stem cells in anti-aging treatments.  GIO World Health senior management have an extensive track record of having provided anti-aging treatments to patients outside of the U.S.  Expansion to non-U.S. locations is intended to utilize local partners to help expedite corporate growth.  Another stream of revenue is expected from GIO World Health’s “Active Cosmetics” line of products that leverage their stem cell technology.  GIO World Health will offer a range of skin care products that will help improve vascularization to skin and healing of inflammation-injured cells.

Their products will focus initially on the “Active Cosmetics” category including: anti-wrinkle, facial serum, daytime skin cream, under eye anti-wrinkle serum, high-end cream and hair vitality formulation.  GIO World Health intends to seek strategic partnerships to help streamline product branding and distribution.  GIO World Health also currently expects to have a revenue stream in the future to be derived from the development of a cost-effective disease-free universal donor (O negative) alternative to donor blood.

The GIO World Health organization will continue to be led under its highly experienced leadership of Dr. Anand Srivastava, Ph.D. and Mr. Deven Patel, who will become executive officers of the post-Closing public company at the Closing. 

 Latest Interview Insights : AiThority Interview with Jessica Stafford, SVP of Consumer Solutions at Cox Automotive

 [To share your insights with us, please write to sghosh@martechseries.com]